Who are Diclofenac sodium gel 3%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Postoperative pain management with metamizole, DICL-SR, ACULAR, Zipsor®, Diclofenac diethylamine 1.16% gel, NSAID (Aceclofenac).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diclofenac-sodium-gel-3.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Diclofenac sodium gel 3% — Competitive Intelligence Brief

Diclofenac sodium gel 3% (Diclofenac sodium gel 3%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID (nonsteroidal anti-inflammatory drug). Area: Pain management / Rheumatology.

marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2 (cyclooxygenase enzymes) Pain management / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Diclofenac sodium gel 3% (Diclofenac sodium gel 3%) — LEO Pharma. Diclofenac sodium inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Diclofenac sodium gel 3% TARGET	Diclofenac sodium gel 3%	LEO Pharma	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2 (cyclooxygenase enzymes)
Postoperative pain management with metamizole	Postoperative pain management with metamizole	Medical University of Silesia	marketed	Non-selective NSAID (nonsteroidal anti-inflammatory drug)	Cyclooxygenase (COX-1 and COX-2)
DICL-SR	DICL-SR	Kunming Baker Norton Pharmaceutical Sales Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
ACULAR	ACULAR	University of South Alabama	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2
Zipsor®	Zipsor®	Depomed	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1 and COX-2 (cyclooxygenase enzymes)
Diclofenac diethylamine 1.16% gel	Diclofenac diethylamine 1.16% gel	Novartis	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2
NSAID (Aceclofenac)	NSAID (Aceclofenac)	Dong-A ST Co., Ltd.	marketed	NSAID (nonsteroidal anti-inflammatory drug)	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID (nonsteroidal anti-inflammatory drug) class)

Depomed · 1 drug in this class
Dong-A ST Co., Ltd. · 1 drug in this class
Handok Inc. · 1 drug in this class
Imprimis Pharmaceuticals, Inc. · 1 drug in this class
Kunming Baker Norton Pharmaceutical Sales Co., Ltd. · 1 drug in this class
LEO Pharma · 1 drug in this class
Novartis · 1 drug in this class
Pfizer · 1 drug in this class
University of South Alabama · 1 drug in this class
ZARS Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Diclofenac sodium gel 3% — Competitive Intelligence Brief. https://druglandscape.com/ci/diclofenac-sodium-gel-3. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab